Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Positive interim data for Immunotherapeutics' MIS416 in chronic progressive MS

This article was originally published in Scrip

Executive Summary

Innate Immunotherapeutics, based in Auckland, New Zealand, said that its lead compound, MIS416 – from its proprietary immune modulating microparticle technology - showed positive Phase I/II interim data, as the preliminary data indicate it was safe and well tolerated. The trial was designed to review the effect of weekly intravenously administered doses in patients with secondary progressive multiple sclerosis.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC017789

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel